Bispecific antibody technology : REGULGENT™
Using our proprietary bispecific antibody technology, we aim to create first-in-class treatments that bring together life-changing technology and biology.
Conventional therapeutic antibodies are limited to binding with just one antigen, while bispecific antibodies can bind to two antigens, making it targeted and increasing efficacy. With this dual-binding feature, it becomes possible to specifically bind to target tissues or cells, and work more effectively.
Bispecific antibodies incorporating Kyowa Kirin's proprietary REGULGENT™ technology are characterized by having two respective antigen-binding sites for two types of antigens, this feature makes it possible for the antibody to act only on the target, for example cancer cells. This unique feature means the treatment is able to leave normal tissues or cells untreated, and therefore maintains a high efficacy with minimal side effects.
REGULGENT™ technology, and the origin of its name
"REGULGENT™" is named after the brightest star, Regulus, in the constellation Leo. Regulus is a quadruple star system composed of four stars that are organized into two pairs, which spin while attracting each other. Kyowa Kirin's proprietary REGULGENT™ technology was named after Regulus as the technology exerts a unique effect by binding to two types of antigens through two respective binding sites, and this is where the celestial name is derived from.
Bispecific antibody technology : REGULGENT™